Abstract
Metabotropic glutamate receptors (mGluRs) are widely known for their roles in synaptic signaling. However, accumulating evidence suggests roles of mGluRs in human malignancies in addition to synaptic transmission. Somatic cell homeostasis presents intriguing possibilities of mGluRs and glutamate signaling as novel targets for human cancers. More recently, aberrant glutamate signaling has been shown to participate in the transformation and maintenance of various cancer types, including glioma, melanoma skin cancer, breast cancer, and prostate cancer, indicating that genes encoding mGluRs, GRMs, can function as oncogenes. Here, we provide a review on the interactions of mGluRs and their ligand, glutamate, in processes that promote the growth of tumors of neuronal and non-neuronal origins. Further, we discuss the evolution of riluzole, a glutamate release inhibitor approved for amyotrophic lateral sclerosis (ALS), but now fashioned as an mGluR1 inhibitor for melanoma therapy and as a radiosensitizer for tumors that have metastasized to the brain. With the success of riluzole, it is not farfetched to believe that other drugs that may act directly or indirectly on other mGluRs can be beneficial for multiple applications.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ali S, Shourideh M, Koochekpour S (2014) Identification of novel GRM1 mutations and single nucleotide polymorphisms in prostate cancer cell lines and tissues. PloS One 9:e103204
Alix JJ, Domingues AM (2011) White matter synapses: form, function, and dysfunction. Neurology 76:397–404
Arcella A, Carpinelli G, Battaglia G, D’Onofrio M, Santoro F, Ngomba RT, Bruno V, Casolini P, Giangaspero F, Nicoletti F (2005) Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro-Oncology 7:236–245
Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, Troost D (2003) Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci 17:2106–2118
Balazs R, Miller S, Romano C, de Vries A, Chun Y, Cotman CW (1997) Metabotropic glutamate receptor mGluR5 in astrocytes: pharmacological properties and agonist regulation. J Neurochem 69:151–163
Ballo MT, Ang KK (2004). Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park) 18, 99–107; discussion 107–110, 113–104
Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GK (2006) Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 64:106–113
Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres Torres KE, Barnard NJ, Kim HJ, Sloane BF, Miller FR, Goydos JS, Gorski DH (2014) Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. PloS One 9:e81126
Barranco SC, Romsdahl MM, Humphrey RM (1971) The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 31:830–833
Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337
Brocke KS, Staufner C, Luksch H, Geiger KD, Stepulak A, Marzahn J, Schackert G, Temme A, Ikonomidou C (2010) Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 9:455–468
Burger M, Burger JA, Hoch RC, Oades Z, Takamori H, Schraufstatter IU (1999) Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi’s sarcoma herpesvirus-G protein-coupled receptor. J Immunol 163:2017–2022
Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychene A, Ortonne JP, Ballotti R (2000) Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 19:2900–2910
Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95
Chaichana KK, Chaichana KL (2011) Diagnosis and treatment options for brain metastasis of melanoma. In: Morton MR (ed) Treatment of Metastatic Melanoma. InTech, Maastricht
Chang HJ, Yoo BC, Lim SB, Jeong SY, Kim WH, Park JG (2005) Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res 11:3288–3295
Chen S, Zhu H, Wetzel WJ, Philbert MA (1996) Spontaneous melanocytosis in transgenic mice. J Invest Dermatol 106:1145–1151
Cheng N, Chytil A, Shyr Y, Joly A, Moses HL (2008) Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 6:1521–1533
Choe ES, Wang JQ (2002) Regulation of transcription factor phosphorylation by metabotropic glutamate receptor-associated signaling pathways in rat striatal neurons. Neuroscience 114:557–565
Choi KY, Chang K, Pickel JM, Badger JD 2nd, Roche KW (2011) Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice. Proc Natl Acad Sci U S A 108:15219–15224
Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca LM, Pallini R, Traficante A, Spinsanti P, Ricci-Vitiani L, Arcella A, De Maria R, Nicoletti F, Battaglia G, Melchiorri D (2013) Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ 20:396–407
D’Onofrio M, Arcella A, Bruno V, Ngomba RT, Battaglia G, Lombari V, Ragona G, Calogero A, Nicoletti F (2003) Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem 84:1288–1295
Daphu I, Horn S, Stieber D, Varughese JK, Spriet E, Dale HA, Skaftnesmo KO, Bjerkvig R, Thorsen F (2014) In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways. Int J Mol Sci 15:8773–8794
DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 104:19345–19350
Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18:54–61
Degenhardt K, White E (2006) A mouse model system to genetically dissect the molecular mechanisms regulating tumorigenesis. Clin Cancer Res 12:5298–5304
Dimski T, Heinen-Lauten J, Krep H (2008) Basal tako-tsubo cardiomyopathy. Induction of a pheochromocytoma after general anesthesia. Anaesthesist 57:143–146
Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47:S233–S241
Eichler AF, Batchelor TT, Henson JW (2007) Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro-Oncology 9:373–377
Esseltine JL, Ferguson SS (2013) Regulation of G protein-coupled receptor trafficking and signaling by Rab GTPases. Small GTPases 4:132–135
Estrela JM, Ortega A, Obrador E (2006) Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43:143–181
Ewend MG, Carey LA, Brem H (1996) Treatment of melanoma metastases in the brain. Semin Surg Oncol 12:429–435
Fairman WA, Amara SG (1999) Functional diversity of excitatory amino acid transporters: ion channel and transport modes. Am J Physiol 277:F481–F486
Fassnacht M, Libe R, Kroiss M, Allolio B (2011) Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 7:323–335
Fendt SM, Bell EL, Keibler MA, Olenchock BA, Mayers JR, Wasylenko TM, Vokes NI, Guarente L, Vander Heiden MG, Stephanopoulos G (2013) Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio in cells. Nat Commun 4:2236
Ferraguti F, Baldani-Guerra B, Corsi M, Nakanishi S, Corti C (1999) Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur J Neurosci 11:2073–2082
Filipp FV, Ratnikov B, De Ingeniis J, Smith JW, Osterman AL, Scott DA (2012) Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell Melanoma Res 25:732–739
Funasaka Y, Harada T, Aiba A, Nishigori C (1996) Expression of metabotropic glutamate receptor and phosphorylated extracellular signal-regulated kinase 1/2 proteins in human melanocytic lesions. Pigment Cell Res 19:656
Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F (2009) Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PloS One 4:e4715
Gameiro PA, Yang J, Metelo AM, Perez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, Lopez-Larrubia P, Stephanopoulos G, Iliopoulos O (2013) In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 17:372–385
Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458:762–765
Gelb T, Pshenichkin S, Hathaway HA, Grajkowska E, Dalley CB, Wolfe BB, Wroblewski JT (2015a) Atypical signaling of metabotropic glutamate receptor 1 in human melanoma cells. Biochem Pharmacol 98:182–189
Gelb T, Pshenichkin S, Rodriguez OC, Hathaway HA, Grajkowska E, DiRaddo JO, Wroblewska B, Yasuda RP, Albanese C, Wolfe BB, Wroblewski JT (2015b) Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas. Oncogene 34:2711–2720
Graus F, Rogers LR, Posner JB (1985) Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 64:16–35
Gutkind JS, Novotny EA, Brann MR, Robbins KC (1991) Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci U S A 88:4703–4707
Habermalz HJ, Fischer JJ (1976) Radiation therapy of malignant melanoma: experience with high individual treatment doses. Cancer 38:2258–2262
Iacovelli L, Arcella A, Battaglia G, Pazzaglia S, Aronica E, Spinsanti P, Caruso A, De Smaele E, Saran A, Gulino A, D'Onofrio M, Giangaspero F, Nicoletti F (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci Off J Soc Neurosci 26:8388–8397
Julius D, Livelli TJ, Jessell TM, Axel R (1989) Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science 244:1057–1062
Karakas E, Regan MC, Furukawa H (2015) Emerging structural insights into the function of ionotropic glutamate receptors. Trends Biochem Sci 40:328–337
Kelly A, Stanley CA (2001) Disorders of glutamate metabolism. Ment Retard Dev Disabil Res Rev 7:287–295
Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG (2011) Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res 17:1807–1814
Koochekpour S (2013) Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer. Asian J Androl 15:212–213
Kuribayashi N, Uchida D, Kinouchi M, Takamaru N, Tamatani T, Nagai H, Miyamoto Y (2013) The role of metabotropic glutamate receptor 5 on the stromal cell-derived factor-1/CXCR4 system in oral cancer. PloS One 8:e80773
Lee HJ, Wall BA, Wangari-Talbot J, Shin SS, Rosenberg S, Chan JL, Namkoong J, Goydos JS, Chen S (2011a) Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res 17:7080–7092
Lee J, Yang EJ, Shin JS, Kim DH, Lee SS, Choi IH (2011b) CKD-712, (S)-1-(alpha-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, Inhibits the NF-kappaB Activation and Augments Akt Activation during TLR4 Signaling. Immune Netw 11:420–423
Li L, Homan KT, Vishnivetskiy SA, Manglik A, Tesmer JJ, Gurevich VV, Gurevich EV (2015) G Protein-coupled Receptor Kinases of the GRK4 Protein Subfamily Phosphorylate Inactive G Protein-coupled Receptors (GPCRs). J Biol Chem 290:10775–10790
Lieu AS, Hwang SL, Howng SL, Chai CY (1999) Brain tumors with hemorrhage. J Formos Med Assoc 98:365–367
Mandybur TI, Nagpaul AS, Pappas Z, Niklowitz WJ (1977) Alzheimer neurofibrillary change in subacute sclerosing panencephalitis. Ann Neurol 1:103–107
Marie SK, Shinjo SM (2011) Metabolism and brain cancer. Clinics (Sao Paulo) 66(Suppl 1):33–43
Marin YE, Chen S (2004) Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. J Mol Med (Berl) 82:735–749
Marin YE, Namkoong J, Cohen-Solal K, Shin SS, Martino JJ, Oka M, Chen S (2006) Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal 18:1279–1286
Martino JJ, Wall BA, Mastrantoni E, Wilimczyk BJ, La Cava SN, Degenhardt K, White E, Chen S (2013) Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene 32:4366–4376
McKay MJ, Kefford RF (1995) The spectrum of in vitro radiosensitivity in four human melanoma cell lines is not accounted for by differential induction or rejoining of DNA double strand breaks. Int J Radiat Oncol Biol Phys 31:345–352
Mehnert JM, Wen Y, Lee JH, Jeong BS, Li J, Dudek Pruski-Clark LL, Kane MM, Lin H, Shih W, Chen S, Goydos JS (2016) A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma. J Clin Oncol 29:8557
Mehta MS, Dolfi SC, Bronfenbrener R, Bilal E, Chen C, Moore D, Lin Y, Rahim H, Aisner S, Kersellius RD, Teh J, Chen S, Toppmeyer DL, Medina DJ, Ganesan S, Vazquez A, Hirshfield KM (2013) Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. PloS One 8:e69851
Miller RG (1999) Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases. J Child Neurol 14:173–179
Moreadith RW, Lehninger AL (1984) The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem 259:6215–6221
Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao Y, Arnold LD, Gibson NW, Ji QS (2009) Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 1:1153–1171
Naarala J, Nykvist P, Tuomala M, Savolainen K (1993) Excitatory amino acid-induced slow biphasic responses of free intracellular calcium in human neuroblastoma cells. FEBS Lett 330:222–226
Namkoong J, Shin SS, Lee HJ, Marin YE, Wall BA, Goydos JS, Chen S (2007) Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 67:2298–2305
Nicholas S, Mathios D, Jackson C, Lim M (2013) Metastatic melanoma to the brain: surgery and radiation is still the standard of care. Curr Treat Options Oncol 14:264–279
Niklas J, Heinzle E (2012) Metabolic flux analysis in systems biology of mammalian cells. Adv Biochem Eng Biotechnol 127:109–132
Nygaard V, Prasmickaite L, Vasiliauskaite K, Clancy T, Hovig E (2014) Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. Oncoscience 1:82–94
Ohtani Y, Harada T, Funasaka Y, Nakao K, Takahara C, Abdel-Daim M, Sakai N, Saito N, Nishigori C, Aiba A (2008) Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 27:7162–7170
Ortiz P, Vanaclocha F, Lopez-Bran E, Esquivias JI, Lopez-Estebaranz JL, Martin-Gonzalez M, Arrue I, Garcia-Romero D, Ochoa C, Gonzalez-Perez A, Ruiz A, Real LM (2007) Genetic analysis of the GRM1 gene in human melanoma susceptibility. Eur J Hum Genet 15:1176–1182
Park SY, Lee SA, Han IH, Yoo BC, Lee SH, Park JY, Cha IH, Kim J, Choi SW (2007) Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 17:81–87
Petralia RS, Wang YX, Niedzielski AS, Wenthold RJ (1996) The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neurosci 71:949–976
Pissimissis N, Papageorgiou E, Lembessis P, Armakolas A, Koutsilieris M (2009) The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res 29:371–377
Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, Zhu H, Robbins C, Makalowska I, Shin SS, Marin Y, Roberts KG, Yudt LM, Chen A, Cheng J, Incao A, Pinkett HW, Graham CL, Dunn K, Crespo-Carbone SM, Mackason KR, Ryan KB, Sinsimer D, Goydos J, Reuhl KR, Eckhaus M, Meltzer PS, Pavan WJ, Trent JM, Chen S (2003) Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 34:108–112
Prickett TD, Samuels Y (2012) Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res 18:4240–4246
Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels Y (2011) Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43:1119–1126
Ribeiro FM, Paquet M, Cregan SP, Ferguson SS (2010) Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol Disord Drug Targets 9:574–595
Roskoski R Jr (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356:323–328
Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patino-Garcia A, Sierrasesumaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF Jr, Yeager M, Hoover RN, Chanock SJ (2013) Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet 45:799–803
Shin SS, Namkoong J, Wall BA, Gleason R, Lee HJ, Chen S (2008) Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res 21:368–378
Spanaki C, Plaitakis A (2012) The role of glutamate dehydrogenase in mammalian ammonia metabolism. Neurotox Res 21:117–127
Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH (2012) Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 132:565–573
Speyer CL, Hachem AH, Assi AA, Johnson JS, DeVries JA, Gorski DH (2014) Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PloS One 9:e88830
Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M, Rzeski W, Staufner C, Brocke KS, Turski L, Ikonomidou C (2009) Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132:435–445
Stepulak A, Luksch H, Uckermann O, Sifringer M, Rzeski W, Polberg K, Kupisz K, Klatka J, Kielbus M, Grabarska A, Marzahn J, Turski L, Ikonomidou C (2011) Glutamate receptors in laryngeal cancer cells. Anticancer Res 31:565–573
Sun RC, Denko NC (2014) Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab 19:285–292
Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7:1010–1015
Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94:701–706
Teh JL, Chen S (2012) Glutamatergic signaling in cellular transformation. Pigment Cell Melanoma Res 25:331–342
Teh JL, Shah R, Shin SS, Wen Y, Mehnert JM, Goydos J, Chen S (2014) Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor. Pigment Cell Melanoma Res 27:621–629
Thandi S, Blank JL, Challiss RA (2002) Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways. J Neurochem 83:1139–1153
Ti TK (1977) Advances in the surgical treatment of peptic ulcer. Med J Malaysia 32:186–188
Van den Bosch L (2006) The causes and mechanism of selective motor neuron death in amyotrophic lateral sclerosis. Verh K Acad Geneeskd Belg 68:249–269
Wall BA, Shin SS, Chen S (2013) Glutamate signaling in human cancers. In: Davids LM (ed) Recent Advances in the Biology, Therapy and Management of Melanoma. InTech, Maastricht
Wall BA, Wangari-Talbot J, Shin SS, Schiff D, Sierra J, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S (2014) Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res 27:263–274
Wall BA, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S (2015) Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells. Pigment Cell Melanoma Res 28:105–109
Wen Y, Li J, Koo J, Shin SS, Lin Y, Jeong BS, Mehnert JM, Chen S, Cohen-Sola KA, Goydos JS (2014) Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression. Cancer Res 74:2499–2509
Willard SS, Koochekpour S (2013) Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci 9:948–959
Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 105:18782–18787
Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB (2011) Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A 108:19611–19616
Wroblewska B, Santi MR, Neale JH (1998) N-acetylaspartylglutamate activates cyclic AMP-coupled metabotropic glutamate receptors in cerebellar astrocytes. Glia 24:172–179
Wronski M, Arbit E (2000) Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 93:9–18
Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A, Kempf J, Shih WJ, Chen S, Goydos JS (2009) A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 15:3896–3902
Yoo BC, Jeon E, Hong SH, Shin YK, Chang HJ, Park JG (2004) Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line. Clin Cancer Res 10:4176–4184
Yu LJ, Wall BA, Chen S (2015) The current management of brain metastasis in melanoma: a focus on riluzole. Expert Rev Neurother 15:779–792
Zamboni N (2011) 13C metabolic flux analysis in complex systems. Curr Opin Biotechnol 22:103–108
Zhang C, Yuan XR, Li HY, Zhao ZJ, Liao YW, Wang XY, Su J, Sang SS, Liu Q (2015) Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway. Cell Physiol Biochem 35:419–432
Zhao H, Desai V, Wang J, Epstein DM, Miglarese M, Buck E (2012) Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol Cancer Ther 11:503–513
Zhu H, Reuhl K, Zhang X, Botha R, Ryan K, Wei J, Chen S (1998) Development of heritable melanoma in transgenic mice. J Invest Dermatol 110:247–252
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Yu, L.J., Wall, B.A., Wangari-Talbot, J., Chen, S. (2017). Metabotropic Glutamate Receptors in Cancer. In: Ngomba, R., Di Giovanni, G., Battaglia, G., Nicoletti, F. (eds) mGLU Receptors. The Receptors, vol 31. Humana Press, Cham. https://doi.org/10.1007/978-3-319-56170-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-56170-7_9
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-56168-4
Online ISBN: 978-3-319-56170-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)